

# James G Wood

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2453064/publications.pdf>

Version: 2024-02-01

57  
papers

939  
citations

566801

15  
h-index

525886

27  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1535  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Evidence compendium and advice on social distancing and other related measures for response to an influenza pandemic. <i>Paediatric Respiratory Reviews</i> , 2015, 16, 119-126.                             | 1.2 | 122       |
| 2  | Influenza-related hospitalisation and death in Australians aged 50 years and older. <i>Vaccine</i> , 2008, 26, 2135-2141.  | 1.7 | 67        |
| 3  | Early analysis of the Australian COVID-19 epidemic. <i>ELife</i> , 2020, 9, .  | 2.8 | 66        |
| 4  | Global production capacity of seasonal and pandemic influenza vaccines in 2019. <i>Vaccine</i> , 2021, 39, 512-520.  | 1.7 | 63        |
| 5  | Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. <i>Vaccine</i> , 2019, 37, A132-A139. | 1.7 | 43        |
| 6  | Sustained measles elimination in Australia and priorities for long term maintenance. <i>Vaccine</i> , 2007, 25, 3574-3580.   | 1.7 | 34        |
| 7  | A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 818-825.                            | 1.4 | 32        |
| 8  | The potential cost-effectiveness of infant pneumococcal vaccines in Australia. <i>Vaccine</i> , 2011, 29, 8077-8085.   | 1.7 | 30        |
| 9  | Current epidemiology of rubella and congenital rubella syndrome in Australia: Progress towards elimination. <i>Vaccine</i> , 2012, 30, 4073-4078.  | 1.7 | 28        |
| 10 | Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies <sup>1</sup> . <i>Emerging Infectious Diseases</i> , 2010, 16, 224-230.  | 2.0 | 27        |
| 11 | Understanding COVID-19 dynamics and the effects of interventions in the Philippines: A mathematical modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 14, 100211.                 | 1.3 | 25        |
| 12 | Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program. <i>Vaccine</i> , 2020, 38, 3646-3652.   | 1.7 | 22        |
| 13 | The impact of active surveillance and health education on an Ebola virus disease cluster in Kono District, Sierra Leone, 2014-2015. <i>BMC Infectious Diseases</i> , 2016, 16, 611.                          | 1.3 | 21        |
| 14 | On realized serial and generation intervals given control measures: The COVID-19 pandemic case. <i>PLoS Computational Biology</i> , 2021, 17, e1008892.  | 1.5 | 21        |
| 15 | Models of strategies for control of rubella and congenital rubella syndrome—A 40 year experience from Australia. <i>Vaccine</i> , 2013, 31, 691-697.   | 1.7 | 20        |
| 16 | Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability. <i>Pharmacoeconomics</i> , 2013, 31, 693-702.                                    | 1.7 | 19        |
| 17 | High rates of latent TB infection in contacts and the wider community in South India. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2017, 111, 55-61.                          | 0.7 | 19        |
| 18 | Estimating the measles effective reproduction number in Australia from routine notification data. <i>Bulletin of the World Health Organization</i> , 2014, 92, 171-177.                                      | 1.5 | 16        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. <i>Vaccine</i> , 2014, 32, 759-765.  | 1.7 | 16        |
| 20 | Impact of high coverage of monovalent human rotavirus vaccine on Emergency Department presentations for rotavirus gastroenteritis. <i>Vaccine</i> , 2015, 33, 1726-1730.  | 1.7 | 16        |
| 21 | Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia. <i>Vaccine</i> , 2009, 27, 313-318.  | 1.7 | 15        |
| 22 | Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. <i>Vaccine</i> , 2016, 34, 320-327.   | 1.7 | 15        |
| 23 | Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic. <i>American Journal of Epidemiology</i> , 2009, 169, 1517-1524.   | 1.6 | 14        |
| 24 | Public health in/as "national security": tuberculosis and the contemporary regime of border control in Australia. <i>Critical Public Health</i> , 2013, 23, 418-431.  | 1.4 | 14        |
| 25 | Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. <i>Communicable Diseases Intelligence Quarterly Report</i> , 2007, 31 Suppl, S1-152.  | 0.6 | 13        |
| 26 | Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. <i>Vaccine</i> , 2017, 35, 4307-4314.  | 1.7 | 12        |
| 27 | Australian rubella serosurvey 2012-2013: On track for elimination?. <i>Vaccine</i> , 2018, 36, 2794-2798.   | 1.7 | 12        |
| 28 | Delay-adjusted age- and sex-specific case fatality rates for COVID-19 in South Korea: Evolution in the estimated risk of mortality throughout the epidemic. <i>International Journal of Infectious Diseases</i> , 2020, 101, 306-311. | 1.5 | 12        |
| 29 | The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia. <i>Vaccine</i> , 2018, 36, 1265-1271.   | 1.7 | 10        |
| 30 | Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges. <i>Pharmacoeconomics</i> , 2016, 34, 723-731.   | 1.7 | 9         |
| 31 | Informing rubella vaccination strategies in East Java, Indonesia through transmission modelling. <i>Vaccine</i> , 2016, 34, 5636-5642.  | 1.7 | 9         |
| 32 | Treatment for pharyngeal gonorrhoea under threat. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1175-1177.   | 4.6 | 9         |
| 33 | Emergence of pertactin-deficient pertussis strains in Australia can be explained by models of vaccine escape. <i>Epidemics</i> , 2020, 31, 100388.  | 1.5 | 9         |
| 34 | Estimating Vaccine Coverage from Serial Trivariate Serologic Data in the Presence of Waning Immunity. <i>Epidemiology</i> , 2015, 26, 381-389.  | 1.2 | 8         |
| 35 | Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia. <i>Vaccine</i> , 2021, 39, 1493-1498.   | 1.7 | 8         |
| 36 | A Study of Failure Events in Drinking Water Systems as a Basis for Comparison and Evaluation of the Efficacy of Potable Reuse Schemes. <i>Environmental Health Insights</i> , 2015, 9s3, EHI.S31749.                                  | 0.6 | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Under-explored assumptions in influenza vaccination models: Implications for the universal vaccination of children. <i>Vaccine</i> , 2012, 30, 5776-5781.   | 1.7 | 6         |
| 38 | Measles control in Australia – threats, opportunities and future needs. <i>Vaccine</i> , 2018, 36, 4393-4398.   | 1.7 | 6         |
| 39 | Modelling the decline and future of hepatitis A transmission in Australia. <i>Journal of Viral Hepatitis</i> , 2019, 26, 199-207.   | 1.0 | 5         |
| 40 | Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016. <i>Journal of Viral Hepatitis</i> , 2020, 27, 74-80.  | 1.0 | 5         |
| 41 | High healthcare resource utilisation due to pertussis in Australian adults aged 65 years and over. <i>Vaccine</i> , 2020, 38, 3553-3559.  | 1.7 | 5         |
| 42 | Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic Review of Existing Literature and Transmission Modelling of Seroprevalence Studies. <i>Infectious Disorders - Drug Targets</i> , 2020, 20, 284-290. | 0.4 | 5         |
| 43 | Quantifying the population effects of vaccination and migration on hepatitis A seroepidemiology in Australia. <i>Vaccine</i> , 2017, 35, 5228-5234.   | 1.7 | 4         |
| 44 | Modelling the in-host dynamics of <i>Neisseria gonorrhoeae</i> infection. <i>Pathogens and Disease</i> , 2019, 77, .  | 0.8 | 4         |
| 45 | Predicting localised measles outbreak potential in Australia. <i>Vaccine</i> , 2015, 33, 1176-1181.   | 1.7 | 3         |
| 46 | Projections of zoster incidence in Australia based on demographic and transmission models of varicella-zoster virus infection. <i>Vaccine</i> , 2017, 35, 6737-6742.  | 1.7 | 3         |
| 47 | Periodicity of varicella-zoster virus in the presence of immune boosting and clinical reinfection with varicella. <i>Theoretical Biology and Medical Modelling</i> , 2015, 12, 6.   | 2.1 | 2         |
| 48 | 472 Long-term effectiveness of 3-dose primary course and 4-year booster dose of pertussis vaccine in Australia. <i>International Journal of Epidemiology</i> , 2021, 50, .  | 0.9 | 2         |
| 49 | Impact of a national immunisation program on herpes zoster incidence in Australia. <i>Journal of Infection</i> , 2022, 84, 537-541.   | 1.7 | 2         |
| 50 | Mathematical Models for the Epidemiology and Evolution of Mycobacterium tuberculosis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1019, 281-307.   | 0.8 | 1         |
| 51 | HG-82 PAEDIATRIC GBM CELLS DEMONSTRATE METABOLIC RESILIENCE TO GROWTH UNDER LIPOPROTEIN DEFICIENT CONDITIONS. <i>Neuro-Oncology</i> , 2016, 18, iii67.2-iii67.  | 0.6 | 0         |
| 52 | O03.4 – Modelling intervention strategies for preventing spread of extensively drug resistant gonorrhoea strains among Australian MSM. , 2019, , .  |     | 0         |
| 53 | O07.5 – The index case’s partnership status is important in predicting the likelihood of persistence of introduced XDR NG among MSM. , 2019, , .  |     | 0         |
| 54 | Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. <i>Vaccine</i> , 2019, 37, 7534.   | 1.7 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | 473 Preventable pertussis burden in Australia within the first year of life by improving vaccination timeliness. <i>International Journal of Epidemiology</i> , 2021, 50, . | 0.9 | 0         |
| 56 | Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia. <i>PLoS Computational Biology</i> , 2021, 17, e1009385.       | 1.5 | 0         |
| 57 | Impact of a structured older persons health assessment on herpes zoster vaccine uptake in Australian primary care. <i>Preventive Medicine</i> , 2022, 155, 106946.          | 1.6 | 0         |